BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ETEX Corporation Announces Distribution Agreement With OrthoPediatrics Corp.


1/27/2010 7:50:18 AM

CAMBRIDGE, Mass., Jan. 26 /PRNewswire/ -- ETEX Corporation, an advanced biomaterials company, announced today a distribution agreement with OrthoPediatrics Corp., of Warsaw, Indiana. OrthoPediatrics will market and sell ETEX's nanocrystalline calcium phosphate on a non-exclusive basis in the United States and Canada.

The ETEX bone graft portfolio complements pediatric orthopedic and spine surgery as illustrated in the recent publication of positive pediatric outcomes using ETEX nanocrystalline calcium phosphate in the treatment of unicamaral bone cysts (Thawrani, et al. Journal of Pediatric Orthopaedics, Vol. 29, Num 5, pp. 511-517, 2009).

Beta-bsm(R) Injectable Paste and Gamma-bsm(R) Moldable Putty set hard with high compressive strength and provide an optimal osteoconductive scaffold for new bone growth. The nanocrystalline formulation mimics the chemical structure of human bone resulting in a predictable remodeling rate.

Brian Ennis, President and CEO of ETEX Corporation, states: "We are pleased to announce the continued expansion of our global distribution network. Partnering with OrthoPediatrics will enable ETEX to focus on the traditionally underserved pediatric market segment. Our rapidly expanding product portfolio is an excellent complement to OrthoPediatrics' biologic and hardware initiatives."

Established in 1989, ETEX Corporation develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.



CONTACT: Shane Doyle of ETEX Corporation, +1-617-577-7270,
sdoyle@etexcorp.com

Web site: http://www.etexcorp.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES